United States-based AbbVie (NYSE: ABBV) announced on Monday that it has submitted an application to the United States Food and Drug Administration (FDA) requiring approval for risankizumab-rzaa (600mg intravenous (IV) induction and 360mg subcutaneous (SC) maintenance therapy), an interleukin-23 (IL-23) inhibitor to treat patients 16 years and older with moderate to severe Crohn's disease.
The submission is based on the safety and efficacy data from three Phase three studies, ADVANCE, MOTIVATE and FORTIFY. The safety profile of all tested doses of the product in moderate to severe Crohn's disease in the ADVANCE, MOTIVATE and FORTIFY studies was consistent with the safety profile of risankizumab-rzaa.
The ADVANCE and MOTIVATE studies are Phase three multicentre, randomised, double-blind, placebo-controlled induction studies aimed at assessing the efficacy and safety of two doses of risankizumab-rzaa, 600mg and 1200mg, in adults with moderate to severe Crohn's disease, compared to placebo.
FDA approval streamlines access to Bristol Myers Squibb CAR T cell therapies
Emmaus Life Sciences' Endari label enhancements receive US FDA approval
Accord Healthcare introduces Dehydrated Alcohol Injection for cardiovascular indications
CARsgen Therapeutics' satri-cel NDA accepted by Chinese regulator
Sanofi receives FDA orphan drug designation for riliprubart in transplant rejection
Hoth Therapeutics reports positive interim results for HT-001 topical therapy
Breckenridge Pharmaceutical's generic for Ablysinol granted final FDA approval
Hemab Therapeutics presents bleeding disorder clinical and preclinical data at ISTH 2025 Congress